Cargando…

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

The epidermal growth factor receptor (EGFR) family plays an important role in breast carcinogenesis. Much interest has been focused recently on its members because of their potential role as prognostic indicators in breast cancer and their involvement in cancer therapy. We have evaluated more than 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Abd El-Rehim, D M, Pinder, S E, Paish, C E, Bell, J A, Rampaul, R S, Blamey, R W, Robertson, J F R, Nicholson, R I, Ellis, I O
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410019/
https://www.ncbi.nlm.nih.gov/pubmed/15480434
http://dx.doi.org/10.1038/sj.bjc.6602184
_version_ 1782155919346368512
author Abd El-Rehim, D M
Pinder, S E
Paish, C E
Bell, J A
Rampaul, R S
Blamey, R W
Robertson, J F R
Nicholson, R I
Ellis, I O
author_facet Abd El-Rehim, D M
Pinder, S E
Paish, C E
Bell, J A
Rampaul, R S
Blamey, R W
Robertson, J F R
Nicholson, R I
Ellis, I O
author_sort Abd El-Rehim, D M
collection PubMed
description The epidermal growth factor receptor (EGFR) family plays an important role in breast carcinogenesis. Much interest has been focused recently on its members because of their potential role as prognostic indicators in breast cancer and their involvement in cancer therapy. We have evaluated more than 1500 cases of invasive breast carcinoma immunohistochemically using tissue microarray technology to examine the expression of EGFR family receptor proteins. We have found that 20.1 and 31.8% of cases were positive for EGFR and c-erbB-2, respectively, and 45 and 45.1% of tumours overexpressed for c-erbB-3 and c-erbB-4, respectively. The expression of either EGFR or c-erbB-2 was associated with other bad prognostic features and with poor outcome. Neither c-erbB-3 nor c-erbB-4 had any association with survival. c-erbB-2 had an independent prognostic effect on overall and disease-free survival (DFS) in all cases, as well as in the subset of breast carcinoma patients with nodal metastases. Several hetero- and homodimeric combinations have been reported between the EGFR members. Those dimers can evoke diverse signal transduction pathways with variable cellular responses. We stratified cases according to their co-expression of receptors into distinct groups with different receptor-positive combinations. Patients whose tumours co-expressed c-erbB-2 and c-erbB-3, as well as those whose tumours co-expressed EGFR, c-erbB-2 and c-erbB-4 showed an unfavourable outcome compared with other groups, while combined c-erbB-3 and c-erbB-4 expression was associated with a better outcome. In cases showing expression of one family member only (homodimers), we found a significant association between c-erbB-4 homodimer-expressing tumours and better DFS. In contrast, patients with c-erbB-2 homodimer-expressing tumours had a significant poorer DFS compared with other cases. These data imply that the combined profile expression patterns of the four receptor family members together provide more accurate information on the tumour behaviour than studying the expression of each receptor individually.
format Text
id pubmed-2410019
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24100192009-09-10 Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma Abd El-Rehim, D M Pinder, S E Paish, C E Bell, J A Rampaul, R S Blamey, R W Robertson, J F R Nicholson, R I Ellis, I O Br J Cancer Molecular and Cellular Pathology The epidermal growth factor receptor (EGFR) family plays an important role in breast carcinogenesis. Much interest has been focused recently on its members because of their potential role as prognostic indicators in breast cancer and their involvement in cancer therapy. We have evaluated more than 1500 cases of invasive breast carcinoma immunohistochemically using tissue microarray technology to examine the expression of EGFR family receptor proteins. We have found that 20.1 and 31.8% of cases were positive for EGFR and c-erbB-2, respectively, and 45 and 45.1% of tumours overexpressed for c-erbB-3 and c-erbB-4, respectively. The expression of either EGFR or c-erbB-2 was associated with other bad prognostic features and with poor outcome. Neither c-erbB-3 nor c-erbB-4 had any association with survival. c-erbB-2 had an independent prognostic effect on overall and disease-free survival (DFS) in all cases, as well as in the subset of breast carcinoma patients with nodal metastases. Several hetero- and homodimeric combinations have been reported between the EGFR members. Those dimers can evoke diverse signal transduction pathways with variable cellular responses. We stratified cases according to their co-expression of receptors into distinct groups with different receptor-positive combinations. Patients whose tumours co-expressed c-erbB-2 and c-erbB-3, as well as those whose tumours co-expressed EGFR, c-erbB-2 and c-erbB-4 showed an unfavourable outcome compared with other groups, while combined c-erbB-3 and c-erbB-4 expression was associated with a better outcome. In cases showing expression of one family member only (homodimers), we found a significant association between c-erbB-4 homodimer-expressing tumours and better DFS. In contrast, patients with c-erbB-2 homodimer-expressing tumours had a significant poorer DFS compared with other cases. These data imply that the combined profile expression patterns of the four receptor family members together provide more accurate information on the tumour behaviour than studying the expression of each receptor individually. Nature Publishing Group 2004-10-18 2004-10-12 /pmc/articles/PMC2410019/ /pubmed/15480434 http://dx.doi.org/10.1038/sj.bjc.6602184 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Molecular and Cellular Pathology
Abd El-Rehim, D M
Pinder, S E
Paish, C E
Bell, J A
Rampaul, R S
Blamey, R W
Robertson, J F R
Nicholson, R I
Ellis, I O
Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
title Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
title_full Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
title_fullStr Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
title_full_unstemmed Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
title_short Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
title_sort expression and co-expression of the members of the epidermal growth factor receptor (egfr) family in invasive breast carcinoma
topic Molecular and Cellular Pathology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410019/
https://www.ncbi.nlm.nih.gov/pubmed/15480434
http://dx.doi.org/10.1038/sj.bjc.6602184
work_keys_str_mv AT abdelrehimdm expressionandcoexpressionofthemembersoftheepidermalgrowthfactorreceptoregfrfamilyininvasivebreastcarcinoma
AT pinderse expressionandcoexpressionofthemembersoftheepidermalgrowthfactorreceptoregfrfamilyininvasivebreastcarcinoma
AT paishce expressionandcoexpressionofthemembersoftheepidermalgrowthfactorreceptoregfrfamilyininvasivebreastcarcinoma
AT bellja expressionandcoexpressionofthemembersoftheepidermalgrowthfactorreceptoregfrfamilyininvasivebreastcarcinoma
AT rampaulrs expressionandcoexpressionofthemembersoftheepidermalgrowthfactorreceptoregfrfamilyininvasivebreastcarcinoma
AT blameyrw expressionandcoexpressionofthemembersoftheepidermalgrowthfactorreceptoregfrfamilyininvasivebreastcarcinoma
AT robertsonjfr expressionandcoexpressionofthemembersoftheepidermalgrowthfactorreceptoregfrfamilyininvasivebreastcarcinoma
AT nicholsonri expressionandcoexpressionofthemembersoftheepidermalgrowthfactorreceptoregfrfamilyininvasivebreastcarcinoma
AT ellisio expressionandcoexpressionofthemembersoftheepidermalgrowthfactorreceptoregfrfamilyininvasivebreastcarcinoma